Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    17360651 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
2 Recruiting Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab
3 Recruiting Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel
4 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and tumor samples

Study has passed its completion date and status has not been verified in more than two years.